A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples
about
Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cellsDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingNovel hybrid GPU-CPU implementation of parallelized Monte Carlo parametric expectation maximization estimation method for population pharmacokinetic data analysis.Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working groupComplex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein.Performance in population models for count data, part II: a new SAEM algorithmImplementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamicsA mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transportNonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensThe use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.Pharmacokinetic alteration of baclofen by multiple oral administration of herbal medicines in ratsComparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.The pharmacokinetics of sertraline in overdose and the effect of activated charcoal.Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patientsTwo mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Network pharmacodynamic models for customized cancer therapy.Nonlinear mixed-effects modelling for single cell estimation: when, why, and how to use itPopulation Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutationsBayesian clinical trials in actionIntegration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy.Pharmacodynamic variability beyond that explained by MICs.Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosaTreating children with acute lymphoblastic leukemia and Down syndrome: pharmacokinetics provides insight into vincristine therapy.Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.Fundamentals of population pharmacokinetic modelling: modelling and software.Use of a linearization approximation facilitating stochastic model building.Fundamentals of Population Pharmacokinetic Modelling : Modelling and Software.High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.Individual predictions based on nonlinear mixed modeling: application to prenatal twin growth.Assessment of penetrant and vehicle mixture properties on transdermal permeability using a mixed effect pharmacokinetic model of ex vivo porcine skin.Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.Using sensitivity equations for computing gradients of the FOCE and FOCEI approximations to the population likelihood.
P2860
Q27347800-1AA9A964-459F-4FE9-A907-D38B44154DAFQ28550711-5A7E4CB2-0249-493D-98E7-35B9BBAA0027Q30664839-DC502BCE-3CEF-4B9A-B0D6-3241B7515814Q30779044-36693D39-203C-452E-AD35-A7B66B4C3D92Q33417707-2FBBCF5B-5B62-4469-980F-C4F94353D1B0Q33493457-486CA3E7-0618-4494-B841-3882D2E12E05Q33743151-629EA7B0-26B0-4ED3-A4D2-B14C157D6A6FQ34060125-3E1DC719-9A38-4CCC-81A9-D3BE7FA8507BQ34381321-ED093ADE-C1E8-4721-B87B-6DDEDE839AD6Q34486811-C88D9D0A-1C1A-42F0-A016-4567D7D6D006Q34501161-791A26EF-142D-4D61-9FEC-B7D2875697D4Q34597749-02B49E7B-DF31-4616-835F-328F3F2BC6E4Q35023742-D7FCD69B-9F19-46C5-9DC4-892D32401CF7Q35065863-C1ECE0D3-3A49-4255-A419-04A6A47ACCD5Q35168882-47710C36-B3DB-4A24-84D8-C5E2F285EBE0Q35688695-8422DC95-EA67-45B7-8233-8B9DA94457A6Q35763355-C1038224-5AED-4A11-A0DD-822821006ACCQ35967888-80336E31-84B5-415A-BE04-82E93C0E0615Q36017372-5B5CD7D4-B8E4-4EAE-BC8D-BC1650B1BBCBQ36076101-88014719-9BE4-4E34-9E54-E407BE57C4BEQ36213618-8B48D662-A2E2-4860-AE8D-CAE428075A17Q36216197-0ED5EB2C-8CCE-4269-8E4E-CB946D59FA73Q36392556-DBE74301-4B40-40A8-9536-BBF922E875E1Q36478646-8C7F46B6-8257-4BC6-920D-3B5F90E7317FQ36757639-0AA5D04C-0E36-4650-8357-C13E627CFF73Q36887819-EA0FE1FB-1EBE-44C7-B704-45A3BE4DD9B0Q36978099-05AA24FB-A0E8-46BD-8F0B-9067FBAA151FQ37538609-FD52E8C7-CD1C-4F9D-83D7-C5436FF1D4F9Q37538623-AB827360-0617-4A46-A70B-1892F8460601Q37538748-81A46B72-D9F7-4330-A360-6F2C6EEBCDD7Q38016955-4A074FAD-45FB-410C-8531-D7D7640710DBQ38555312-A9F9F915-E917-45A4-829F-E1D6DA44DE01Q38930366-34470A92-5D79-4DFC-A981-E99A075392E3Q39170967-986D2DA7-5CC3-4075-BBA7-BE1C6AB11E74Q39645070-0A82ADDD-E833-4C1D-9B2C-DE6E00F39515Q39721162-2904217A-0F27-4060-B0F1-79ACF3B5785AQ39742601-B471F925-E429-4870-A44F-838DB71EC300Q40306198-84D94AF6-14A9-4D39-90C5-F6E8CEB23956Q40657200-76F51566-F6A4-46DE-875B-22C17D8A10B8Q40674519-195FCA2A-4924-4125-AC49-6DC890824769
P2860
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A survey of population analysi ...... codynamic models with examples
@ast
A survey of population analysi ...... codynamic models with examples
@en
type
label
A survey of population analysi ...... codynamic models with examples
@ast
A survey of population analysi ...... codynamic models with examples
@en
prefLabel
A survey of population analysi ...... codynamic models with examples
@ast
A survey of population analysi ...... codynamic models with examples
@en
P2093
P2860
P356
P1433
P1476
A survey of population analysi ...... codynamic models with examples
@en
P2093
Robert J Bauer
Serge Guzy
P2860
P2888
P304
P356
10.1208/AAPSJ0901007
P407
P577
2007-03-02T00:00:00Z
P5875
P6179
1018774119